VJHemOnc is committed to improving our service to you

ASH 2018 | BELIEVE: β-thalassemia treatment with luspatercept reduces transfusion burden

VJHemOnc is committed to improving our service to you

Maria Domenica Cappellini

An erythroid maturation defect causing ineffectibe erythropoiesis and red blood cell maturation is associated with the condition β-thalassemia. Luspatercept is a first-in-class erythroid maturation agent, which is under development for the treatment of this condition. Maria Domenica Cappellini, MD, of the University of Milan, Milan, Italy, presents here the results of the Phase III BELIEVE trial (NCT02604433) of luspatercept vs. a placebo in adults with β-thalassemia who require regular red blood cell transfusions. Excitingly, luspatercept significantly reduced transfusion burden and was generally well-tolerated.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter